X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Operating Leases for 8 consecutive years, with $465000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 78.7% year-over-year to $465000.0; the trailing twelve-month figure through Jun 2026 stood at $465000.0 (down 78.7% YoY), and the FY2025 full-year result was $994000.0, down 29.5% from the prior year.
• Operating Leases slipped to $465000.0 in Q2 2026 per XFOR's latest filing, from $733000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $5.6 million in Q1 2022 and bottomed at $465000.0 in Q2 2026.
• Historically, Operating Leases has averaged $3.0 million across 5 years, with a median of $3.1 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases dropped 13.37% in 2022, then tumbled 78.7% in 2026.
• Over 5 years, Operating Leases stood at $3.6 million in 2022, then retreated by 27.5% to $2.6 million in 2023, then plunged by 46.02% to $1.4 million in 2024, then retreated by 29.5% to $994000.0 in 2025, then plunged by 53.22% to $465000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $465000.0, $733000.0, and $994000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.